Cargando…
Sex-based clinical and immunological differences in COVID-19
BACKGROUND: Males and females differ in their immunological responses to foreign pathogens. However, most of the current COVID-19 clinical practices and trials do not take the sex factor into consideration. METHODS: We performed a sex-based comparative analysis for the clinical outcomes, peripheral...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8256650/ https://www.ncbi.nlm.nih.gov/pubmed/34225644 http://dx.doi.org/10.1186/s12879-021-06313-2 |
_version_ | 1783718140628172800 |
---|---|
author | Huang, Bin Cai, Yun Li, Ning Li, Kening Wang, Zhihua Li, Lu Wu, Lingxiang Zhu, Mengyan Li, Jie Wang, Ziyu Wu, Min Li, Wanlin Wu, Wei Zhang, Lishen Xia, Xinyi Wang, Shukui Chen, Hongshan Wang, Qianghu |
author_facet | Huang, Bin Cai, Yun Li, Ning Li, Kening Wang, Zhihua Li, Lu Wu, Lingxiang Zhu, Mengyan Li, Jie Wang, Ziyu Wu, Min Li, Wanlin Wu, Wei Zhang, Lishen Xia, Xinyi Wang, Shukui Chen, Hongshan Wang, Qianghu |
author_sort | Huang, Bin |
collection | PubMed |
description | BACKGROUND: Males and females differ in their immunological responses to foreign pathogens. However, most of the current COVID-19 clinical practices and trials do not take the sex factor into consideration. METHODS: We performed a sex-based comparative analysis for the clinical outcomes, peripheral immune cells, and severe acute respiratory syndrome coronavirus (SARS-CoV-2) specific antibody levels of 1558 males and 1499 females COVID-19 patients from a single center. The lymphocyte subgroups were measured by Flow cytometry. The total antibody, Spike protein (S)-, receptor binding domain (RBD)-, and nucleoprotein (N)- specific IgM and IgG levels were measured by chemiluminescence. RESULTS: We found that male patients had approximately two-fold rates of ICU admission (4.7% vs. 2.7% in males and females, respectively, P = 0.005) and mortality (3% vs. 1.4%, in males and females, respectively, P = 0.004) than female patients. Survival analysis revealed that the male sex is an independent risk factor for death from COVID-19 (adjusted hazard ratio [HR] = 2.22, 95% confidence interval [CI]: 1.3–3.6, P = 0.003). The level of inflammatory cytokines in peripheral blood was higher in males during hospitalization. The renal (102/1588 [6.5%] vs. 63/1499 [4.2%], in males and females, respectively, P = 0.002) and hepatic abnormality (650/1588 [40.9%] vs. 475/1499 [31.7%], P = 0.003) were more common in male patients than in female patients. By analyzing dynamic changes of lymphocyte subsets after symptom onset, we found that the percentage of CD19+ B cells and CD4+ T cells was generally higher in female patients during the disease course of COVID-19. Notably, the protective RBD-specific IgG against SARS-CoV-2 sharply increased and reached a peak in the fourth week after symptom onset in female patients, while gradually increased and reached a peak in the seventh week after symptom onset in male patients. CONCLUSIONS: Males had an unfavorable prognosis, higher inflammation, a lower percentage of lymphocytes, and indolent antibody responses during SARS-CoV-2 infection and recovery. Early medical intervention and close monitoring are important, especially for male COVID-19 patients. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12879-021-06313-2. |
format | Online Article Text |
id | pubmed-8256650 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-82566502021-07-06 Sex-based clinical and immunological differences in COVID-19 Huang, Bin Cai, Yun Li, Ning Li, Kening Wang, Zhihua Li, Lu Wu, Lingxiang Zhu, Mengyan Li, Jie Wang, Ziyu Wu, Min Li, Wanlin Wu, Wei Zhang, Lishen Xia, Xinyi Wang, Shukui Chen, Hongshan Wang, Qianghu BMC Infect Dis Research Article BACKGROUND: Males and females differ in their immunological responses to foreign pathogens. However, most of the current COVID-19 clinical practices and trials do not take the sex factor into consideration. METHODS: We performed a sex-based comparative analysis for the clinical outcomes, peripheral immune cells, and severe acute respiratory syndrome coronavirus (SARS-CoV-2) specific antibody levels of 1558 males and 1499 females COVID-19 patients from a single center. The lymphocyte subgroups were measured by Flow cytometry. The total antibody, Spike protein (S)-, receptor binding domain (RBD)-, and nucleoprotein (N)- specific IgM and IgG levels were measured by chemiluminescence. RESULTS: We found that male patients had approximately two-fold rates of ICU admission (4.7% vs. 2.7% in males and females, respectively, P = 0.005) and mortality (3% vs. 1.4%, in males and females, respectively, P = 0.004) than female patients. Survival analysis revealed that the male sex is an independent risk factor for death from COVID-19 (adjusted hazard ratio [HR] = 2.22, 95% confidence interval [CI]: 1.3–3.6, P = 0.003). The level of inflammatory cytokines in peripheral blood was higher in males during hospitalization. The renal (102/1588 [6.5%] vs. 63/1499 [4.2%], in males and females, respectively, P = 0.002) and hepatic abnormality (650/1588 [40.9%] vs. 475/1499 [31.7%], P = 0.003) were more common in male patients than in female patients. By analyzing dynamic changes of lymphocyte subsets after symptom onset, we found that the percentage of CD19+ B cells and CD4+ T cells was generally higher in female patients during the disease course of COVID-19. Notably, the protective RBD-specific IgG against SARS-CoV-2 sharply increased and reached a peak in the fourth week after symptom onset in female patients, while gradually increased and reached a peak in the seventh week after symptom onset in male patients. CONCLUSIONS: Males had an unfavorable prognosis, higher inflammation, a lower percentage of lymphocytes, and indolent antibody responses during SARS-CoV-2 infection and recovery. Early medical intervention and close monitoring are important, especially for male COVID-19 patients. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12879-021-06313-2. BioMed Central 2021-07-05 /pmc/articles/PMC8256650/ /pubmed/34225644 http://dx.doi.org/10.1186/s12879-021-06313-2 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Article Huang, Bin Cai, Yun Li, Ning Li, Kening Wang, Zhihua Li, Lu Wu, Lingxiang Zhu, Mengyan Li, Jie Wang, Ziyu Wu, Min Li, Wanlin Wu, Wei Zhang, Lishen Xia, Xinyi Wang, Shukui Chen, Hongshan Wang, Qianghu Sex-based clinical and immunological differences in COVID-19 |
title | Sex-based clinical and immunological differences in COVID-19 |
title_full | Sex-based clinical and immunological differences in COVID-19 |
title_fullStr | Sex-based clinical and immunological differences in COVID-19 |
title_full_unstemmed | Sex-based clinical and immunological differences in COVID-19 |
title_short | Sex-based clinical and immunological differences in COVID-19 |
title_sort | sex-based clinical and immunological differences in covid-19 |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8256650/ https://www.ncbi.nlm.nih.gov/pubmed/34225644 http://dx.doi.org/10.1186/s12879-021-06313-2 |
work_keys_str_mv | AT huangbin sexbasedclinicalandimmunologicaldifferencesincovid19 AT caiyun sexbasedclinicalandimmunologicaldifferencesincovid19 AT lining sexbasedclinicalandimmunologicaldifferencesincovid19 AT likening sexbasedclinicalandimmunologicaldifferencesincovid19 AT wangzhihua sexbasedclinicalandimmunologicaldifferencesincovid19 AT lilu sexbasedclinicalandimmunologicaldifferencesincovid19 AT wulingxiang sexbasedclinicalandimmunologicaldifferencesincovid19 AT zhumengyan sexbasedclinicalandimmunologicaldifferencesincovid19 AT lijie sexbasedclinicalandimmunologicaldifferencesincovid19 AT wangziyu sexbasedclinicalandimmunologicaldifferencesincovid19 AT wumin sexbasedclinicalandimmunologicaldifferencesincovid19 AT liwanlin sexbasedclinicalandimmunologicaldifferencesincovid19 AT wuwei sexbasedclinicalandimmunologicaldifferencesincovid19 AT zhanglishen sexbasedclinicalandimmunologicaldifferencesincovid19 AT xiaxinyi sexbasedclinicalandimmunologicaldifferencesincovid19 AT wangshukui sexbasedclinicalandimmunologicaldifferencesincovid19 AT chenhongshan sexbasedclinicalandimmunologicaldifferencesincovid19 AT wangqianghu sexbasedclinicalandimmunologicaldifferencesincovid19 |